Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00757614|
Recruitment Status : Unknown
Verified April 2010 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : September 23, 2008
Last Update Posted : August 26, 2013
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer in East Anglia, Trent, or West Midlands of the United Kingdom.
|Condition or disease||Intervention/treatment|
|Bladder Cancer Brain and Central Nervous System Tumors Esophageal Cancer Intraocular Melanoma Kidney Cancer Lymphoma Melanoma (Skin) Pancreatic Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter||Genetic: DNA analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis Other: questionnaire administration|
- To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors.
- Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series.
- To estimate the age and sex-specific risks associated with variants in predisposition genes.
- To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors.
OUTLINE: This is a multicenter study.
Patients complete a detailed epidemiological questionnaire that includes information on education, occupation, smoking habits, alcohol consumption, height, weight, reproductive history (age at menarche, age at pregnancies, parity, and age at menopause), oral contraceptive use, hormone replacement therapy use, family history of cancer, and past medical history.
Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.
In addition to the cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, and prostate cancer are recruited for the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-PROSTATE.
|Study Type :||Observational|
|Estimated Enrollment :||14000 participants|
|Official Title:||A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands|
|Study Start Date :||February 2008|
- Acquisition of epidemiological information and biological material
- Identification of novel cancer susceptibility genes
- Estimation of the age and sex-specific risks associated with variants in predisposition genes
- Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757614
|University of Cambridge Cancer Research UK||Recruiting|
|Cambridge, England, United Kingdom, CB1 8RN|
|Contact: Contact Person 44-122-374-0166 email@example.com|
|Study Chair:||Paul Pharoah, MD||Cancer Research UK|